Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | VHL | P40337 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 7/20 | 0.38 |
| ▸ | NPC1 | O15118 | 6/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2328124 | 0.82 | NOTUM (0.43) | SMN1; SMN2VHLMAPTRAB9ANPC1 | |
| SCHEMBL18819583 | 0.80 | SMN1; SMN2 (0.40) | SMN1; SMN2VHLMAPTRAB9ANPC1 | |
| SCHEMBL1703668 | 0.80 | ALDH1A1 (0.44) | SMN1; SMN2VHLMAPTRAB9ANPC1 | |
| SCHEMBL6251 | 0.80 | VHL (0.60) | SMN1; SMN2VHLMAPTPOLBMEN1 | |
| SCHEMBL10520054 | 0.78 | RAB9A (0.46) | SMN1; SMN2MAPTRAB9ANPC1MAPK1 | |
| Hydrochloric Acid SCHEMBL1375734 | 0.78 | VHL (0.58) | SMN1; SMN2VHLMAPTPOLBMEN1 | |
| SCHEMBL4033216 | 0.78 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTRAB9ANPC1MAPK1 | |
| SCHEMBL1809792 | 0.78 | ALDH1A1 (0.42) | SMN1; SMN2VHLMAPTRAB9ANPC1 | |
| SCHEMBL18527352 | 0.78 | CYP2C9 (0.38) | SMN1; SMN2VHLMAPTMAPK1 | |
| SCHEMBL7423467 | 0.78 | VHL (0.38) | SMN1; SMN2VHLMAPTPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674111-B2 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-18 | — | — | US | disclosed |
| EP-2440536-B1 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-06 | — | — | EP | disclosed |
| US-20120115916-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2440536-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143158-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115916-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | P2RX1, GLP1R, P2RX7 | SMN1; SMN2 3814/4885VHL 3912/4885MAPT 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.